SIETES :: 92261 citas

Resultados de la búsqueda por ALOGLIPTINA REFINAR BÚSQUEDA

1.

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102513]

2.

Anónimo. Gliptines: pancréatites. Prescrire 2017;37:262. [Ref.ID 101534]

3.

Anónimo. Gliptines: insuffisances cardiaques. Prescrire 2017;37:190-2. [Ref.ID 101457]

4.

Anónimo. Drugs for type 2 diabetes. Med Lett Drugs Ther 2017;59:9-18. [Ref.ID 101372]

5.

Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]

6.

Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]

7.

Anónimo. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. FDA Drug Administration 2016:1. [Ref.ID 100107]

8.

Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, for the CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016;374:1145-54. [Ref.ID 100077]

9.

Bolen SD, Maruthur NM. The safety of incretin based drug treatments for type 2 diabetes. BMJ 2016;352:i801. [Ref.ID 100062]

10.

Anónimo. Nuevos hipoglucemiantes: sin noticias de eficacia y nuevos efectos adversos. Butlletí Groc 2015;28:11-4. [Ref.ID 99840]

11.

Anónimo. Artralgia grave en pacientes tratados con gliptinas. Butlletí de Farmacovigilància de Catalunya 2015;13:14-5. [Ref.ID 99833]

12.

Holman RR, Peterson ED. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2479. [Ref.ID 99762]

13.

Rutter MK, Wright AK, Ashcroft DM. Sitagliptin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:2478. [Ref.ID 99761]

14.

Anónimo. DPP-4 Inhibitors for type 2 diabetes: drug safety communication - May cause severe joint pain. FDA U.S. Food and Drug Administration 2015:28 de agosto. [Ref.ID 99420]

15.

Anónimo. Informe de posicionamiento terapéutico de la alogliptina (Vipidia). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2015:1 de julio. [Ref.ID 99271]

16.

Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015;385:2017-117. [Ref.ID 99159]

17.

Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, for the EXAMINE Investigators. Heart failure and mortality ocutcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76. [Ref.ID 99158]

18.

Standl E, Schnell O. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 2015;385:2022-4. [Ref.ID 99156]

19.

Anónimo. Alogliptine seule ou associée. Prescrire 2015;35:326-7. [Ref.ID 99130]

20.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. [Ref.ID 96331]